Cancer Institute A national cancer institute
designated cancer center

Michael Link

Publication Details

  • Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.

    Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA, Pappo AS, Link MP, Grier HE, Wiener ES, Breneman JC, Raney RB, Maurer HM, Donaldson SS. J Clin Oncol. 2001; 19 (20): 4058-64

    To identify which patients with rhabdomyosarcoma and microscopic residual disease (group II) are likely to not respond to therapy.

    PubMedID: 11600608

Stanford Medicine Resources:

Footer Links: